Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It
Royalties Will Fuel R&D Expansion
The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.
You may also be interested in...
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.
Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.